Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis.

[1]  Dietmar Winkler,et al.  Enhanced Serotonin Transporter Function during Depression in Seasonal Affective Disorder , 2008, Neuropsychopharmacology.

[2]  Treatment of seasonal affective disorder with duloxetine: an open-label study. , 2008, Pharmacopsychiatry.

[3]  S. Kasper,et al.  Escitalopram in seasonal affective disorder: results of an open trial. , 2007, Pharmacopsychiatry.

[4]  Rupert Lanzenberger,et al.  Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study , 2007, Psychopharmacology.

[5]  E. Demir,et al.  Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: A single-blind, randomized clinical trial , 2006, Advances in therapy.

[6]  M. Flores-Ramos,et al.  Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. , 2006, Journal of affective disorders.

[7]  S. Kasper,et al.  Treatment of seasonal affective disorder , 2006, Expert review of neurotherapeutics.

[8]  O. Bodlund,et al.  Efficacy and Tolerability of Reboxetine Compared with Citalopram: A Double-blind Study in Patients with Major Depressive Disorder , 2006, Journal of clinical psychopharmacology.

[9]  A. Leon,et al.  Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. , 2005, The Journal of clinical psychiatry.

[10]  Ove Wiborg,et al.  The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors , 2003, European Neuropsychopharmacology.

[11]  A. Sarandol,et al.  [Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder]. , 2005, Turk psikiyatri dergisi = Turkish journal of psychiatry.

[12]  S. Kasper,et al.  Bright light therapy in seasonal affective disorder – does it suffice? , 2004, European Neuropsychopharmacology.

[13]  S. Chiechio,et al.  Prediction of the response to citalopram and reboxetine in post-stroke depressed patients , 2004, Psychopharmacology.

[14]  S. Kasper,et al.  Effects of tryptophan depletion and catecholamine depletion on immune parameters in patients with seasonal affective disorder in remission with light therapy , 2003, Biological Psychiatry.

[15]  J. Rybakowski,et al.  Reboxetine, a New Noradrenaline Selective Antidepressant, Is at Least as Effective as Fluoxetine in the Treatment of Depression , 2002, Journal of clinical psychopharmacology.

[16]  S. Kasper,et al.  Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls , 2001, Psychological Medicine.

[17]  Reboxetine in seasonal affective disorder: an open trial , 2001, European Neuropsychopharmacology.

[18]  S. Kasper,et al.  Reboxetine: the first selective noradrenaline re-uptake inhibitor , 2000, Expert opinion on pharmacotherapy.

[19]  Alexander Neumeister,et al.  [123I]-β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder , 2000, Biological Psychiatry.

[20]  H. Möller,et al.  Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. , 1999, International clinical psychopharmacology.

[21]  S. Kasper,et al.  Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. , 1998, Archives of general psychiatry.

[22]  A. Dubini,et al.  Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale , 1997, European Neuropsychopharmacology.

[23]  D. Murphy,et al.  Effects of meta-chlorophenylpiperazine infusions in patients with seasonal affective disorder and healthy control subjects. Diurnal responses and nocturnal regulatory mechanisms. , 1997, Archives of general psychiatry.

[24]  M. Philipp,et al.  Guidelines for the implementation of drug utilization observation (DUO) studies in psychopharmacological therapy. The "Phase IV Research" Task-Force of the Association for Neuropsychopharmacology and Pharmacopsychiatry (AGNP). , 1997, Pharmacopsychiatry.

[25]  P. Caffarra,et al.  Abnormal serotonergic control of prolactin and cortisol secretion in patients with seasonal affective disorder , 1993, Psychoneuroendocrinology.

[26]  Hj Norussis,et al.  SPSS for Windows , 1993 .

[27]  S. Dilsaver,et al.  The efficacy of bupropion in winter depression: results of an open trial. , 1992, The Journal of clinical psychiatry.

[28]  Janet B W Williams,et al.  A structured interview guide for the Hamilton Depression Rating Scale. , 1988, Archives of general psychiatry.

[29]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[30]  F. Goodwin,et al.  Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. , 1984, Archives of general psychiatry.

[31]  P Bech,et al.  The Hamilton Depression Scale , 1981, Acta psychiatrica Scandinavica.

[32]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[33]  L. Heilmeyer.  Fortschritte der Therapie , 1948 .